Trial Profile
Multicenter, Observational Trial to Determine the Response Rate of Sorafenib and Donor Lymphocyte Infusions (DLI) Versus Best Available Treatment (BAT) in FLT3-ITD-mutant AML Relapse After Allogeneic Hematopoietic Cell Transplantation
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Sorafenib (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms SIRA
- 19 Aug 2016 New trial record